JW THERAP-B(02126) granted 2 million stock options.
WuXi AppTec Co., Ltd. - B (02126) announced that on May 19, 2026, the company granted a total of 2 million share options to Mr. Tian Feng, the Company's Executive Director and CEO, in accordance with the terms of the Company's first public offering incentive plan adopted on October 14, 2020.
JW THERAP-B(02126) announced that on May 19, 2026, the company granted a total of 2 million share options to Mr. Tian Feng, the executive director and CEO of the company, according to the terms of the company's initial public offering incentive plan adopted on October 14, 2020.
Related Articles
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
STRONG PETRO (00852): Expected to incur a loss of approximately USD 10.7 million in a transaction involving asphalt products trading.
On May 19th, CONANT OPTICAL (02276) spent 6.201 million Hong Kong dollars to repurchase 144,000 shares.
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
STRONG PETRO (00852): Expected to incur a loss of approximately USD 10.7 million in a transaction involving asphalt products trading.
On May 19th, CONANT OPTICAL (02276) spent 6.201 million Hong Kong dollars to repurchase 144,000 shares.
